Patently Innovative

Dr Ron A. Bouchard is an intellectual property lawyer and scholar, specializing in the innovation, regulation, and litigation of biomedical products. His career has focused on the science, law, policy, regulation, and commercialization of medical technologies. He began his career as a medical scientist, completing a PhD and Postdoctoral Fellowship in the field of ion channel biophysics and Ca2+ imaging. He shifted focus to obtain a law degree specializing in pharmaceutical and biotechnology law and has been involved in the prosecution, acquisition, financing, distribution, and litigation of intellectual property rights. Dr Bouchard has appeared before the Federal Court of Canada and the Supreme Court of Canada. He has consulted with firms, universities, governments, and international organizations on legal, regulatory, and policy issues. He worked with the Government of Canada on its platforms for drug regulation and public private partnerships in technology commercialization. His research has been funded by federal and provincial funding agencies and private endowments. His scholarly expertise is focused on the intellectual property and regulatory aspects of therapeutic product development, including global aspects of technology commercialization, patenting, licensing, and regulatory approval, and empirical assessment of the impact of government stimulus packages and regulation on technology innovation. Dr Bouchard currently is involved with a new global consortium of scholars, physicians and economists studying the impact of emerging forms of patent law on the availability and costs of essential medications in developed and developing nations: the Consortium Study of Global Pharmaceutical Linkage.

Dedication

Acknowledgements

List of figures and tables

List of abbreviations

About the author

Chapter 1: Introduction

Abstract:

1.1 The emergence of global pharmaceutical linkage

1.2 Canadian pharmaceutical linkage regulations

1.3 Organization

Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy

Abstract:

2.1 Drug approval

2.2 Patents

2.3 Linkage regulations

2.4 IPR rights and innovation policy

Chapter 3: Empirical analysis of drug approval

Abstract:

3.1 Introduction

3.2 Analysis

3.3 Results

3.4 Discussion

3.5 Interpretation of data

3.6 Study limitations

3.7 Assessing the lifecycle approach: the long view

3.8 Government as representative public agent

3.9 Summary and conclusions

Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage

Abstract:

4.1 Introduction

4.2 Methods

4.3 Results

4.4 Discussion

Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts

Abstract:

5.1 Introduction

5.2 Methods

5.3 Results

5.4 Discussion

5.5 Summary and conclusions

Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?

Abstract:

6.1 Introduction

6.2 Debate preceding Bill C-91

6.3 ‘Original policy intent’

6.4 ‘Patent-specific’ analysis

6.5 Statutory interpretation

6.6 Revisiting the empirical data

6.7 Summary and conclusions

Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage

Abstract:

7.1 Hypotheses regarding cluster-based drug development

7.2 Globalization of pharmaceutical linkage

Index